Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04904692 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Virological and Immunological Monitoring in Patients (suspected Of/confirmed With) COVID-19

Study acronym: Co-Vim
StatusUnknown
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Study Identification, Study Status, Oversightv5
  3. Study completion date: Sep 30, 2023 to Sep 30, 2024v4
  4. Re-verified, no change to tracked fieldsv3
  5. Primary completion date changed from estimate of Sep 20, 2021 to Jul 23, 2020
    • Study completion date: Sep 20, 2021 to Sep 30, 2023
    • Secondary endpoints: 3 to 4
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, observational multicentric study. The study population entails adult patients hospitalized with a high clinical suspicion of COVID-19 and consists of two study arms (SARS-CoV2- vs. SARS-CoV2+).This combined fundamental research project has a dual goal: on the one hand assessing immunological predisposing factors for severe infection and investigating the immunological impact of SARS-CoV2 infection, on the other hand studying viral characteristics. Furthermore, a substudy will examine the pharmacokinetics and pharmacodynamics of hydroxychloroquine in patients receiving this antiviral treatment (REVIVE susbstudy). To answer these research questions, samples will be collected from patients with a high clinical suspicion of COVID-19, hospitalized at UZ Gent and 2 participating hospitals in Ghent (AZ Maria Middelares en AZ Jan Palfijn).
Trial Details
NCT Number NCT04904692
Lead Sponsor University Hospital, Ghent
Collaborators: Fund for Scientific Research, Flanders, Belgium, Chan Zuckerberg Initiative, Flanders Institute for Biotechnology
Conditions
(from sponsor)		 COVID-19
Related terms COVID-19
Enrollment 109 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov